MapLight Therapeutics (MPLT) CEO sells 19,187 shares to cover taxes

Rhea-AI Filing Summary

MapLight Therapeutics, Inc. director and CEO Christopher A. Kroeger reported stock sales primarily tied to tax withholding. On April 15–16, he disposed of a total of 19,187 shares of Voting Common Stock at weighted average prices in the $26–$28 range. A footnote states these sales represent shares required to cover statutory tax withholding obligations related to vesting restricted stock units, indicating they are compensation-driven rather than discretionary portfolio moves. After these transactions, Kroeger holds 1,630,564 shares directly and 101,190 shares indirectly through the C&M Kroeger Nominee Trust, where he has voting and dispositive power.

Insights

Insider transactions analyst

CEO’s 19,187-share sale appears mainly tax-driven and routine.

Christopher A. Kroeger, CEO of MapLight Therapeutics, Inc., reported selling 19,187 shares of Voting Common Stock over April 15–16. Although coded as open-market sales, a footnote explains the shares were required to cover statutory tax withholding on vesting restricted stock units.

This framing makes the activity more mechanical than discretionary. Following the sales, he still directly holds 1,630,564 shares, with another 101,190 shares held indirectly via the C&M Kroeger Nominee Trust, where he has voting and dispositive power. The absence of derivative positions in this filing suggests no options-related event here.

The scale of the net disposition relative to his total reported holdings appears limited, and the tax-withholding purpose reduces its informational value about his view of the stock. Subsequent company filings may further contextualize future equity awards and related tax settlements.

Insider Trade Summary

Net Seller: 19,187 shares ($521,146)

Net Sell 4 txns

Insider Kroeger Christopher A.

Role Chief Executive Officer

Sold 19,187 shs ($521K)

Type	Security	Shares	Price	Value
Sale	Voting Common Stock	2,477	$27.01	$67K
Sale	Voting Common Stock	7,575	$27.49	$208K
Sale	Voting Common Stock	9,135	$26.93	$246K
holding	Voting Common Stock	--	--	--

Holdings After Transaction: Voting Common Stock — 1,638,139 shares (Direct); Voting Common Stock — 101,190 shares (Indirect, See footnote)

Footnotes (1)

1. Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.33 to $27.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4). The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.2201 to $27.2197 inclusive. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.22 to $27.9898 inclusive. The shares are held by the C&M Kroeger Nominee Trust, of which the Reporting Person is co-trustee with his spouse and has voting and dispositive power.

Key Figures

Total shares sold: 19,187 shares Sale price range (set 1): $26.33–$27.29 Sale price range (set 2): $26.2201–$27.2197 +3 more

6 metrics

Total shares sold 19,187 shares Net disposals over April 15–16, 2026

Sale price range (set 1) $26.33–$27.29 Weighted average price range in one sale group

Sale price range (set 2) $26.2201–$27.2197 Weighted average price range in second sale group

Sale price range (set 3) $27.22–$27.9898 Weighted average price range in third sale group

Direct holdings after transactions 1,630,564 shares Voting Common Stock held directly post-sale

Indirect holdings in trust 101,190 shares Held by C&M Kroeger Nominee Trust with voting and dispositive power

Key Terms

restricted stock units, statutory tax withholding obligations, weighted average price, voting and dispositive power, +1 more

5 terms

restricted stock units financial

"in connection with the vesting of the restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

statutory tax withholding obligations financial

"required to be sold to cover the statutory tax withholding obligations"

weighted average price financial

"The price reported is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

voting and dispositive power financial

"the Reporting Person is co-trustee with his spouse and has voting and dispositive power."

Voting Common Stock financial

"security_title": "Voting Common Stock""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kroeger Christopher A.

(Last) (First) (Middle)

C/O MAPLIGHT THERAPEUTICS, INC.

800 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Voting Common Stock	04/15/2026		S		9,135(1)	D	$26.93(2)	1,640,616	D
Voting Common Stock	04/16/2026		S		2,477(1)	D	$27.01(3)	1,638,139	D
Voting Common Stock	04/16/2026		S		7,575(1)	D	$27.49(4)	1,630,564	D
Voting Common Stock								101,190	I	See footnote(5)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.33 to $27.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4).

3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.2201 to $27.2197 inclusive.

4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.22 to $27.9898 inclusive.

5. The shares are held by the C&M Kroeger Nominee Trust, of which the Reporting Person is co-trustee with his spouse and has voting and dispositive power.

	/s/ Kristopher L. Hanson, Attorney-in-Fact	04/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

How many MapLight Therapeutics (MPLT) shares did the CEO dispose of in this Form 4?

The CEO, Christopher A. Kroeger, disposed of 19,187 shares of Voting Common Stock. These transactions occurred on April 15–16 and are described as covering statutory tax withholding obligations tied to vesting restricted stock units, rather than purely discretionary sales.

At what prices did MapLight Therapeutics (MPLT) shares sell in the reported CEO transactions?

The reported sales used weighted average prices, with ranges from $26.33 to $27.29, $26.2201 to $27.2197, and $27.22 to $27.9898. These ranges reflect multiple individual trades aggregated into each transaction’s weighted average price disclosure.

Why did the MapLight Therapeutics (MPLT) CEO sell 19,187 shares according to the Form 4 footnotes?

A footnote explains the 19,187 shares represent stock required to be sold to cover statutory tax withholding obligations arising from vesting restricted stock units. This indicates the sales were largely compensation- and tax-related rather than purely discretionary trading decisions.

How many MapLight Therapeutics (MPLT) shares does the CEO hold after these transactions?

After the reported sales, Christopher A. Kroeger directly holds 1,630,564 shares of Voting Common Stock. He also indirectly holds 101,190 shares through the C&M Kroeger Nominee Trust, where he is co-trustee with his spouse and has voting and dispositive power.

Are any MapLight Therapeutics (MPLT) shares held indirectly for the CEO in this Form 4?

Yes. The filing shows 101,190 shares held indirectly by the C&M Kroeger Nominee Trust. A footnote states the CEO is co-trustee with his spouse and has voting and dispositive power over these shares, reflecting an additional indirect ownership stake.

Does the MapLight Therapeutics (MPLT) Form 4 indicate any remaining derivative positions for the CEO?

The derivative summary in the data is empty, showing no derivative transactions and no remaining derivative positions in this particular filing. The reported activity focuses solely on non-derivative Voting Common Stock and tax-related sales following restricted stock unit vesting.